As reported on Pharmaceutical Business Review, Affinia Therapeutics has been granted orphan drug designation by the US Food and Drug Administration (FDA) for AFTX-201, an experimental gene therapy being developed to treat BAG3-associated dilated cardiomyopathy (DCM), a rare inherited heart condition that can lead to progressive heart failure.
The designation follows the FDA’s earlier Fast Track recognition for the program and highlights the unmet medical need faced by patients with BAG3-related DCM. Individuals with the disorder often experience worsening cardiac function and reduced life expectancy despite currently available treatments.
AFTX-201 is a one-time intravenous gene therapy designed to address the genetic cause of the disease. The treatment delivers a functional BAG3 gene using Affinia’s proprietary viral capsid technology, which is engineered to target heart tissue efficiently while potentially requiring lower doses than conventional gene therapy approaches.
The therapy is currently being evaluated in the Phase I/II UPBEAT clinical trial, which is underway at multiple sites across the United States and Canada. The study is enrolling adults between the ages of 18 and 55 who have been diagnosed with BAG3-associated DCM and are experiencing limitations in daily activities due to heart failure symptoms.
Commenting on the regulatory milestone, Affinia Therapeutics Chief Medical Officer Dr. Hideo Makimura said the orphan drug designation, combined with the program’s recent Fast Track status, represents important progress for AFTX-201. He noted that the therapy is intended to correct the underlying genetic defect responsible for the disease and expressed optimism about advancing clinical development while recruitment for the UPBEAT study continues.
BAG3-associated DCM is linked to genetic variants that reduce production of the BAG3 protein in cardiac muscle cells. Published research suggests that BAG3 mutations account for approximately 2.3% to 3.6% of dilated cardiomyopathy cases worldwide.
The FDA’s orphan drug program is designed to encourage the development of therapies for rare diseases. Companies receiving the designation may qualify for benefits including tax incentives, waived regulatory fees, and the possibility of market exclusivity if the product ultimately gains regulatory approval.
The announcement comes as Affinia continues to strengthen its financial position. In October 2025, the company secured $40 million in Series C financing led by New Enterprise Associates, providing additional support for advancement of its gene therapy pipeline, including AFTX-201.
